Replies to post #243206 on Biotech Values

[swampboots]

ADVM and EYPT are (to me) great examples of a poker hand which can be played to sustain their share prices, on a bet their drugs can squeeze enough earlier progress juicing up PR's (on to me unfathomable explanations) of their nearness to remarkable progress for an essentially unmet disease solution..

[DewDiligence]

ADVM—(-12%)—reports purportedly-positive interim phase-2 data_in wAMD:

https://www.globenewswire.com/news-release/2024/07/17/2914283/32452/en/Adverum-Biotechnologies-Presents-Positive-Ixo-vec-Clinical-Data-from-the-26-Week-Interim-Analysis-of-the-LUNA-Phase-2-Trial-at-the-2024-ASRS-Annual-Meeting.html

Note: The header of this post is almost identical to the header of the immediately preceding post, which is not a clerical error.